{
  "ticker": "IIQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959474",
  "id": "02959474",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250618",
  "time": "0847",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250618/pdf/06kvjpp65ql147.pdf",
  "summary": "- **Breakthrough Therapeutic Efficacy**: INOVIQ's CAR-exosomes destroyed **88% of triple-negative breast cancer (TNBC) and lung cancer cells** in lab tests within 96 hours.  \n- **Platform Validation**: Demonstrates potential for **\"off-the-shelf\" therapy** with cost, safety, and efficacy advantages over traditional CAR-T cell therapies.  \n- **Next Steps**: Proceeding to **animal studies** (preclinical) before human trials.  \n- **Material Impact**: Positive preclinical results could enhance valuation due to potential **transformative cancer treatment** and platform applicability to multiple cancers.  \n\n*Omitted: Operational/financial metrics, timelines for clinical milestones.*",
  "usage": {
    "prompt_tokens": 1377,
    "completion_tokens": 140,
    "total_tokens": 1517,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T22:54:13.086754"
}